Marc S. Rudoltz

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Andreas Hochhaus, S G O'Brien, François Guilhot et al. · Leukemia · 2009 · 845 citations

Medicine, Hematology, Oncology +5

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford et al. · Blood · 2010 · 487 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

Jörge E. Cortes, Michele Baccarani, François Guilhot et al. · Journal of Clinical Oncology · 2009 · 285 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Stephen G. O’Brien, François Guilhot, John M. Goldman et al. · Blood · 2008 · 173 citations

Pharmacy, Oncology, Pharmacotherapy +8

Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis

Marc S. Rudoltz, Alia Benammar, Mohammed Mohiuddin · International Journal of Radiation Oncology*Biology*Physics · 1993 · 129 citations

Medicine, Oncology, Neoplasia +12